United States:
Stay Denied; Expedited Appeal Granted In Namenda Product Hopping Suit
14 January 2015
Patterson Belknap Webb & Tyler LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Following the S.D.N.Y.'s award to the New York State
Attorney General of an injunction requiring Actavis to continue
distributing the immediate-release tablet version of its dementia
drug, Namenda (which we
analyzed previously), the Second Circuit Court of Appeals has
denied Actavis' request for a stay of
the injunction pending appeal. It has, however, granted
Actavis' request for an expedited appellate briefing
schedule.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Antitrust/Competition Law from United States
US Antitrust Agencies Release Final Revised Merger Guidelines
Goodwin Procter LLP
On December 18, 2023, the Federal Trade Commission and the Antitrust Division of the Department of Justice released the final version of revised Merger Guidelines, a set of principles Agencies use in their review of mergers and acquisitions.
NCAA Updates Guidance On Transfer Rules
McLane Middleton, Professional Association
In December 2023, the State of Ohio sued the NCAA in the United States District Court for the District of West Virginia, challenging the organization's transfer waiver policy...
